B precursor type acute leukaemia
Not yet recruitingPhase II study of autologous enriched T‑cell therapy expressing CD19 and CD22 CARs in Philadelphia‑negative B‑precursor ALL patients with measurable residual disease
Phase II study of autologous enriched T‑cell therapy expressing CD19 and CD22 CARs in Philadelphia‑negative B‑precursor ALL patients with measurable residual disease
- Disease:B precursor type acute leukaemia
- Substances:–
Germany- Participants:18–64 years · 65+ years
- Sponsor:Goethe University Frankfurt









